Medicinal Cannabis Industry Australia (MCIA) is the voice for Australia’s medicinal cannabis industry and is focused on representing the mutual interests of members to build a sustainable and responsible industry that is trusted, valued, puts patients first and recognised for its quality and innovation.
Epilepsy Action Australia (EAA) as the leading and oldest provider of epilepsy services nationwide, focuses on improving self-management skills, increasing wider public understanding of this devastating condition, and are at the forefront of partnering and funding research into interventions and treatments. EAA also operate CanGuide, an independent and impartial service providing information on cannabis-based medicine.
Continue reading “MCIA and Epilepsy Action Australia partner to deliver independent information for the medicinal cannabis industry”
Growing The Industry Through Research, Collaboration and Innovation: Register now for ACannabis 2023
Continue reading “Don’t miss ACannabis 2023: Register Now”
In October MCIA released data obtained from the Office of Drug Control that revealed the volume of medicinal cannabis produced by Australian cultivators, along with volumes of imports and exports. MCIA has now obtained data from TGA that sheds light on the nature of products sold in Australia.
Continue reading “MCIA investigations shine further light on Australia’s medicinal cannabis industry”
On Thursday 27 October 2022 MCIA hosted a fireside chat and networking function. The focus of the event was on tips and tricks for the OTC market, product registration and advertising environment for S3 CBD.
Continue reading “MCIA Event: Tips and Tricks for the OTC Market”
On 28 October 2022 held a workshop on “Tips for successfully engaging with Human Research Ethics Committee”. This workshop was designed to provide a forum for participants from across the medicinal cannabis industry, and particularly medicinal cannabis companies and research organisations, to discuss approaches to successfully engaging with HREC in the area of clinical trials involving unregistered medicinal cannabis therapeutic goods.
Continue reading “MCIA Workshop: Tips for successfully engaging with Human Research Ethics Committee”
Please join MCIA and industry colleagues for a fireside chat and networking function. The focus will be on tips and tricks for the OTC market, product registration and advertising environment for S3 CBD.
Continue reading “MCIA Networking Event: Tips and Tricks for the OTC Market”
Take advantage of our Early Bird pricing and secure your ticket today. Prices inc GST
Continue reading “ACannabis 2023: Registrations Open”
Carefully chosen as the venue, ACannabis is thrilled to align with this world class venue that has a strong emphasis on sustainability and the environment.
Continue reading “ACannabis 2023 will be held at the newly built CENTREPIECE in Melbourne.”
This workshop is designed to provide a forum for participants from across the medicinal cannabis industry, and particularly medicinal cannabis companies and research organisations, to discuss approaches to successfully engaging with HREC in the area of clinical trials involving unregistered medicinal cannabis therapeutic goods.
MCIA is supporting this to assist in enabling and encouraging robust clinical research in the sector.
Date: 28 October 2022
Time: 11:00am – 1.00pm (AEST)
Virtual: Zoom link will be provided when you register
The workshop will cover:
- Sponsor obligations and responsibilities
- Botanical drug product and quality control
- Preclinical evidence
- Trial design
- Dr Melinda Thompson, Head of Regulatory Affairs & Quality Systems Source Certain and Chair of MCIA Research Working Group
- Professor Andrew McLachlan, Head of School & Dean of Pharmacy, University of Sydney
- Biljana Georgievska, EVP Commercial, Nucleus Network
- Dr Anastasia Suraev, The Lambert Initiative
Please register below if you would like to attend and you will receive a confirmation email containing information about joining the meeting.
ACannabis is back
ACannabis has established itself as a professional, credible industry event on the Australian medicinal cannabis calendar. Speakers, partners and delegates continue to rate the conference highly for format, content and organisation and we can’t wait to come back face to face in 2023.
Continue reading “ACannabis 2023: Growing The Industry Through Research, Collaboration and Innovation.”